Sareum Hldgs Plc (SAR) - Stock Price & Dividends
Exchange: London Exchange • Country: United Kingdom • Currency: GBX • Type: Common Stock • ISIN: GB00BMC3RJ87
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom. Web URL: https://www.sareum.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
SAR Stock Overview
Market Cap in USD | 35m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 2004-10-11 |
SAR Stock Ratings
Growth 5y | -0.19 |
Fundamental | -68.8 |
Dividend | - |
Rel. Performance vs Sector | -13.25 |
Analysts | - |
Fair Price Momentum | 31.95 GBX |
Fair Price DCF | - |
SAR Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
SAR Growth Ratios
Growth 12m | -68.24% |
Growth Correlation 12m | -87% |
Growth Correlation 3m | -21% |
CAGR 5y | 5.22% |
CAGR/Mean DD 5y | 0.11 |
Sharpe Ratio 12m | -0.64 |
Alpha vs SP500 12m | -89.15 |
Beta vs SP500 5y weekly | 0.65 |
ValueRay RSI | 97.83 |
Volatility GJR Garch 1y | 108.79% |
Price / SMA 50 | 73.59% |
Price / SMA 200 | -27.16% |
Current Volume | 1596k |
Average Volume 20d | 2715.2k |
External Links for SAR Stock
What is the price of SAR stocks?
As of May 16, 2024, the stock is trading at GBX 39.70 with a total of 1,595,970 shares traded.
Over the past week, the price has changed by +63.71%, over one month by +148.13%, over three months by -0.75% and over the past year by -68.24%.
As of May 16, 2024, the stock is trading at GBX 39.70 with a total of 1,595,970 shares traded.
Over the past week, the price has changed by +63.71%, over one month by +148.13%, over three months by -0.75% and over the past year by -68.24%.
What is the forecast for SAR stock price target?
According to ValueRays Forecast Model, SAR Sareum Hldgs Plc will be worth about 35.3 in May 2025. The stock is currently trading at 39.70. This means that the stock has a potential downside of -11.11%.
According to ValueRays Forecast Model, SAR Sareum Hldgs Plc will be worth about 35.3 in May 2025. The stock is currently trading at 39.70. This means that the stock has a potential downside of -11.11%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 176 | 343 |
Analysts Target Price | - | - |
ValueRay Target Price | 35.3 | -11.1 |